How Ph.D. was paid
$4.3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Carsten Brunn, Ph.D.President and Chief Executive Officer | $674,000 | $973,475 | $2,314,320 | $363,960 | $4,113 | $4,329,868 |
| Blaine DavisChief Financial Officer | $475,860 | $372,460 | $884,122 | $205,572 | $11,913 | $1,949,927 |
| Milos Miljkovic, M.D.Chief Medical Officer | $439,000 | $321,670 | $766,422 | $118,530 | $11,913 | $1,657,535 |
| Christopher Jewell, Ph.D.Former Chief Scientific Officer | $390,665 | $375,046 | $661,814 | $144,200 | $443,982 | $2,015,707 |
| Metin Kurtoglu, M.D., Ph.D.Former Chief Technology Officer | $163,494 | $775,931 | $984,442 | $60,427 | $489,740 | $2,474,034 |
What changed and why
- $4.3MCarsten Brunn received total compensation of $4,329,868 in fiscal 2025, down from $7,314,211 in fiscal 2024.
- $674KBase salary for the Chief Executive Officer increased to $674,000 for fiscal 2025.
- Annual performance bonus for the Chief Executive Officer was determined based on company clinical and business goals.
- Christopher Jewell ceased service as Chief Scientific Officer effective November 14, 2025.
- Metin Kurtoglu ceased service as Chief Technology Officer effective May 1, 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.